The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Lantus sales are dropping fast because ... The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got ...

Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine ... of people who rely on daily injections of insulin for treatment ...

“For the millions of people who rely on daily injections of insulin for treatment of diabetes ... biosimilar that was interchangeable with Lantus (Sanofi) and, according to Dr. Janet Woodcock ...

Other common side effects may include injection site reactions ... U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%. Sanofi said it would ...

Telehealth platform GoodRx has become the latest company to offer people with diabetes access to insulin for $35 per month— regardless of whether they have insurance. GoodRx said in a statement ...

Insulin glargine (Lantus; Aventis Pharmaceuticals ... These molecular changes cause the drug to precipitate upon subcutaneous injection, increasing stability and duration of action.

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

Semglee has an identical amino acid sequence to Lantus and is approved for ... Instruct patients to always check the insulin label before injection. Severe, life-threatening generalized allergy ...

injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...